CEO SUMMARY: If BioImagene’s CEO is to be believed, the company is ready to deliver a digital pathology system that is robust and affordable, even in settings with just two or three pathologists. One key to the BioImagene strategy is “per scan” pricing that avoids the need for upfront capital to acquire its system. Confident
Tag: pathology imaging
CEO SUMMARY: Digital pathology imaging systems are finding uses in all phases of drug discovery (discovery, pre-clinical, clinical trials), as well as education, research, and clinical. One hurdle to widespread adoption of fully digitized, whole-slide pathology imaging systems is FDA clearance that allows the use of this technology for primary diagnosis. Executives at two of
IMMEDIATELY AFTER GENERAL ELECTRIC ANNOUNCED its partnership with the University of Pittsburgh Medical Center (UPMC) on June 5 to develop a fully integrated digital pathology system, we took a closer look at how some pioneering pathologists are using digital imaging systems in their daily clinical practice.
What we found is that the technology is fairly well
CEO SUMMARY: It’s a new joint venture with the potential to transform surgical pathology. General Electric Healthcare has extensive experience at supporting physicians’ work flow with digitized imaging systems, plus ample experience with molecular bio-markers. The University of Pittsburgh Medical Center’s pathology department is a world leader in whole-slide imaging and digitized pathology systems. Together,
CEO SUMMARY: Advances in computer hardware, software and support systems such as scanners are bringing the era of full pathology digitization closer to reality. Last week, in San Diego, California, an enthusiastic crowd of several hundred gathered to learn how laboratories, hospitals, and researchers are taking the first steps to digitize different areas of pathology
CEO SUMMARY: Biggest deal in recent weeks was the $1.55 billion Beckman Coulter paid to acquire BioSite and its Triage BNP test. But the most interesting news may be the entry of 3M Corporation into clinical diagnostics, based on its acquisition of Acolyte Biomedica Ltd., a company which offers a five-hour rapid culture-based MRSA test.
IF THE NEW BUSINESS AGREEMENT between Ventana Medical Systems, Inc. and TriPath Imaging, Inc. is successful, then the anatomic pathology laboratory may have a very different look in future years.
Last week, Ventana Medical Systems, Inc. announced a five-year global supply agreement with TriPath Imaging, Inc. that involves two primary objectives. First, Ventana will put its